Erivedge: first targeted therapy for basal cell carcinomaNew drug indicated in adults for the treatment of histologically confirmed metastatic basal cell carcinoma or locally advanced basal cell carcinoma that is inappropriate for surgery or radiotherapy Leading the Way: what’s new in Diabetes Care?A look at new Canadian guidelines, toolkits, drug indications, dosage forms, and devices for diabetes New Drug: Perjeta for the treatment of HER2-positive metastatic breast cancer New drug is a recombinant, humanized, monoclonal antibody. Clinical Feature: What’s new in diabetes care? A look at new Canadian guidelines, toolkits, drug indications, dosage forms, and devices for diabetes Leading Edge: Solid tumour smackdown ‘Colour Outside the Lines’ to drive change in Canadian healthcare Leading health organizations collaborate to support reverse innovation challenge Under investigation A summary of drugs in late-stage development in Canada Drug News: November 2012 One year of adjuvant trastuzumab best for breast cancer Six months of treatment may be worse and two years is no better Drug News: October 2012 First Previous 6 7 8 9 10 Next Last
